These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12575486)

  • 1. Biomarkers and proof of concept.
    Ferber G
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl C():35-40. PubMed ID: 12575486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in early cancer drug development: limited utility.
    Glassman RH; Ratain MJ
    Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
    Severino ME; Dubose RF; Patterson SD
    IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ultimate model organism: progress in experimental medicine.
    Littman BH; Williams SA
    Nat Rev Drug Discov; 2005 Aug; 4(8):631-8. PubMed ID: 16056389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials.
    Cressie N; Biele J
    Biometrics; 1994 Sep; 50(3):700-11. PubMed ID: 7981396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of futility analyses for 'proof of concept' trials.
    Lawrence Gould A
    Stat Med; 2005 Jun; 24(12):1815-35. PubMed ID: 15815997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of biomarkers of neurological disease.
    Dunckley T; Coon KD; Stephan DA
    Drug Discov Today; 2005 Mar; 10(5):326-34. PubMed ID: 15749281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the early phase development of new analgesics by human pain biomarkers.
    Arendt-Nielsen L; Hoeck HC
    Expert Rev Neurother; 2011 Nov; 11(11):1631-51. PubMed ID: 22014141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials.
    Millen BA; Dmitrienko A; Song G
    J Biopharm Stat; 2014; 24(1):94-109. PubMed ID: 24392980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian versus Frequentist statistical modeling: a debate for hit selection from HTS campaigns.
    Cloutier LM; Sirois S
    Drug Discov Today; 2008 Jun; 13(11-12):536-42. PubMed ID: 18549981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
    Pallay A
    J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.